RecruitingNot ApplicableNCT03645486

Lentiviral Gene Therapy for CGD

Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

10 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Granulomatous Disease

Summary

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Infusion of lentiviral TYF-CGD-modified autologous stem cells for people with chronic granulomatous disease. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICInfusion of lentiviral TYF-CGD-modified autologous stem cells

Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight

Locations(1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03645486

Related Trials

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

NCT051899251 location

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

NCT054631331 location

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT072846411 location